Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shares were up 3.5% during mid-day trading on Monday . The stock traded as high as $11.95 and last traded at $11.80, with a volume of 247,775 shares changing hands. The stock had previously closed at $11.40.

Several research analysts have recently issued reports on VNDA shares. Jefferies Group reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Vanda Pharmaceuticals in a research note on Saturday, May 7th. Brean Capital set a $20.00 price objective on Vanda Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday. Piper Jaffray Cos. reaffirmed a “buy” rating and issued a $16.00 price objective on shares of Vanda Pharmaceuticals in a research note on Thursday. Finally, Zacks Investment Research downgraded Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, July 6th. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $15.92.

The firm’s 50 day moving average price is $11.20 and its 200-day moving average price is $9.32. The stock’s market capitalization is $524.90 million.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its earnings results on Wednesday, July 27th. The biopharmaceutical company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.12. During the same quarter in the prior year, the business earned ($0.13) EPS. The company earned $36.02 million during the quarter, compared to the consensus estimate of $36.03 million. The firm’s revenue for the quarter was up 30.6% compared to the same quarter last year. On average, analysts forecast that Vanda Pharmaceuticals Inc. will post ($0.77) earnings per share for the current fiscal year.

An institutional investor recently raised its position in Vanda Pharmaceuticals stock. Bank of Montreal Can raised its position in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 23.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,208,918 shares of the biopharmaceutical company’s stock after buying an additional 228,074 shares during the period. Bank of Montreal Can owned 2.82% of Vanda Pharmaceuticals worth $11,255,000 as of its most recent filing with the SEC.

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products for the treatment of central nervous system (CNS) disorders. The Company’s product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.